Oncology - Page 1

Ipsen, Active Biotech conclude half of planned recruitment in tasquinimod study
Tuesday, May 22, 2012 Active Biotech and Ipsen have announced that 600 patients have been recruited in the global, pivotal, randomised, double-blind, placebo-controlled Phase 3 study of tasquinimod, used to...

Tokai announces positive galeterone data from Phase 1 study
Monday, May 21, 2012 Tokai Pharmaceuticals has reported additional data from a Phase 1 safety and proof-of-concept study investigating galeterone (TOK-001), in patients with castration-resistant prostate cancer...

Tivozanib drug shows superior PFS over sorafenib in Phase 3 study
Thursday, May 17, 2012 Aveo Oncology and Astellas Pharma have announced positive findings from the Tivozanib Versus Sorafenib in 1st line Advanced RCC (TIVO-1) study of its investigational agent...

Galectin begins Phase 1/2 study of GM-CT-01 combination therapy
Wednesday, May 16, 2012 Galectin Therapeutics has dosed the first patient in a Phase 1/2 trial demonstrating the safety and efficacy of its carbohydrate-based galectin inhibitor compound, GM-CT-01, in combination with...

Onconova rigosertib drug advances into Phase 2 study
Monday, May 14, 2012 Onconova Therapeutics has announced that it is advancing the oral formulation of rigosertib (Estybon, ON 01910.Na), an anti-cancer agent, into a new Phase 2...

Genta begins Tesetaxel drug study in US, Europe and Asia
Thursday, May 10, 2012 Genta has enrolled the first patient in a new randomised clinical trial of its drug compound, Tesetaxel, used for the treatment of patients with advanced gastric...

Millennium and Seattle Genetics initiate Phase 3 lymphoma drug study
Tuesday, May 08, 2012 Millennium and Seattle Genetics have commenced an international pivotal Phase 3 clinical trial, evaluating Adcetris (brentuximab vedotin) in patients with CD30-expressing cutaneous T-cell...

Idera reports Phase 2 study data of IMO-2055 combination therapy
Monday, May 07, 2012 Idera Pharmaceuticals has announced the results from its Phase 2 clinical trial evaluating IMO-2055 in combination with Erbitux (cetuximab) for the treatment of recurrent or metastatic...

Ficlatuzumab combination therapy found superior to gefitinib monotherapy
Thursday, May 03, 2012 Aveo Pharmaceuticals has announced the preliminary data from the randomised Phase 2 study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase inhibitor (TKI),...

Novartis Afinitor drug wins FDA approval
Friday, April 27, 2012 Novartis' Afinitor (everolimus) tablets have been approved by the US Food and Drug Administration (FDA) for treating adult patients with renal angiomyolipomas and tuberous sclerosis complex...

Morphotek begins Phase II cancer drug study
Wednesday, April 18, 2012 Morphotek, a subsidiary of Eisai, has initiated a multi-centre Phase II study investigating the safety and efficacy of MORAb-004 in the treatment of metastatic colorectal cancer that is...

Alchemia updates on Phase III cancer drug study
Monday, April 16, 2012 Alchemia has announced an update regarding the pivotal Phase III clinical study of its anti-cancer drug, HA-Irinotecan, which is currently being used to treat patients with 2nd/3rd line...

Lonza, Agennix enter into Talactoferrin drug development deal
Friday, April 13, 2012 Swiss drug maker Lonza and Germany's Agennix have signed a development and manufacturing agreement for the production of Agennix's oral Dendritic Cell Mediated Immunotherapy (DCMI),...

FDA approves Marshall Edwards cancer drug IND application
Wednesday, April 11, 2012 The US Food and Drug Administration (FDA) has granted Investigational New Drug (IND) application for Marshall Edwards' mitochondrial inhibitor, ME-344, used for the treatment of...

Syndax begins Phase 1/2 study of Entinostat combination therapy
Tuesday, April 10, 2012 Syndax Pharmaceuticals has announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have commenced a Phase 1/2 study of its...

Presage Biosciences signs cancer research deal with Millennium
Tuesday, April 10, 2012 Presage Biosciences, a biotechnology company, has entered into a cancer research agreement with Millennium: The Takeda Oncology...

BIND reports positive preclinical data of cancer drug
Thursday, April 05, 2012 Clinical-stage biopharmaceutical company BIND Biosciences has reported promising preclinical data from the Phase 1 clinical study of BIND-014 in patients with advanced or metastatic...

ImmunoGen begins Phase II of cancer drug study
Monday, April 02, 2012 ImmunoGen has started Phase II of a study designed to evaluate the safety and efficacy of its IMGN901 (lorvotuzumab mertansine) product candidate, used for first-line treatment of small-cell...

Genentech T-DM1 drug found to extend survival time in cancer patients
Monday, April 02, 2012 Genentech's Trastuzumab emtansine (T-DM1) has reported positive results from the randomised Phase III study conducted in patients with HER2-positive metastatic breast cancer (mBC) who...

Clovis Oncology concludes patient enrollment in LEAP trial
Wednesday, March 28, 2012 Clovis Oncology has completed patient enrolment in its pivotal Low hENT1 and Adenocarcinoma of the Pancreas (LEAP) study of CO-101 versus gemcitabine in metastatic pancreatic cancer...